Background

Statins reduce cardiovascular events through lipid-lowering and pleiotropic effects, including anti-inflammatory, antioxidant, plaque-stabilizing, and endothelial-protective actions. High-dose statin loading before percutaneous coronary intervention may reduce periprocedural myocardial injury compared with standard-dose therapy.

Objective

To compare the efficacy and safety of high-dose versus standard-dose statins administered before coronary intervention.

Methods

A multicenter comparative study included 760 patients undergoing elective or urgent PCI. Patients received either high-dose statin therapy before PCI or standard-dose statin therapy. Primary outcomes included periprocedural myocardial injury and major adverse cardiovascular events at 12 months.

Results

Periprocedural myocardial injury occurred in 8.9% of patients receiving high-dose statins and 14.7% receiving standard-dose statins. Twelve-month MACE was 9.8% in the high-dose group and 13.5% in the standard-dose group. No significant increase in liver enzyme elevation or myopathy was observed with high-dose therapy.

Conclusion

High-dose statin therapy before PCI was associated with reduced periprocedural myocardial injury and favorable clinical outcomes without major safety concerns. Routine pre-procedural high-intensity statin therapy should be considered in eligible patients undergoing coronary intervention.